Contact Us
Drug Search Results
More Filters [+]

CB-020

Alternative Names: CB-020, CB020, CB 020
Latest Update: 2022-12-12
Latest Update Note: News Article

Product Description

CB-020 is a iNK cell candidate for the treatment of solid tumors. (Sourced from: https://www.cariboubio.com/pipeline/)

Mechanisms of Action: CAR-T

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Caribou Biosciences
Company Location: BERKELEY CA 94710
Company CEO: Rachel E. Haurwitz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CB-020

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

12/12/2022

News Article

 Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions